PCRX · Pacira BioSciences, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-11 | RIKER LAUREN |
Senior Vice President, Finance |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. |
Common Stock
|
6,115 |
| 2026-06-10 | YANG MICHAEL J. |
EVP and CCO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
6,405 |
| 2026-06-10 | Young Alethia |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
6,405 |
| 2026-06-10 | CHRISTIE CHRISTOPHER |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Stock Option (Right to Buy)
|
10,891 |
| 2026-06-10 | Froimson Mark |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Stock Option (Right to Buy)
|
10,891 |
| 2026-06-10 | Froimson Mark |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
6,405 |
| 2026-06-10 | BIGAL MARCELO |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Stock Option (Right to Buy)
|
10,891 |
| 2026-06-10 | Brege Laura |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
6,405 |
| 2026-06-10 | WIGGANS THOMAS G |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Stock Option (Right to Buy)
|
32,675 |
| 2026-06-10 | Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Stock Option (Right to Buy)
|
10,891 |
| 2026-06-10 | CHRISTIE CHRISTOPHER |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
6,405 |
| 2026-06-10 | Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
6,405 |
| 2026-06-10 | Young Alethia |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Stock Option (Right to Buy)
|
10,891 |
| 2026-06-10 | BIGAL MARCELO |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
6,405 |
| 2026-06-10 | YANG MICHAEL J. |
EVP and CCO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Stock Option (Right to Buy)
|
10,891 |
| 2026-06-10 | Brege Laura |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Stock Option (Right to Buy)
|
10,891 |
| 2026-06-09 | WIGGANS THOMAS G |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-04 | WILLIAMS KRISTEN |
Chief Administrative Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025. |
Common Stock
|
10,259 |
| 2026-06-03 | RIKER LAUREN |
Senior Vice President, Finance |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
3,187 |
| 2026-06-03 | SLONIN JONATHAN |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
4,728 |
| 2026-06-03 | WILLIAMS KRISTEN |
Chief Administrative Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
8,528 |
| 2026-04-23 | Cross Shawn |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Stock Option (Right to Buy)
|
12,941 |
| 2026-04-23 | Cross Shawn |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
Common Stock
|
12,941 |
| 2026-04-23 | Cross Shawn |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
12,941 |
| 2026-04-22 | Cross Shawn |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Stock Option (Right to Buy)
|
1,500 |
| 2026-04-22 | Cross Shawn |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
Common Stock
|
1,500 |
| 2026-04-22 | Cross Shawn |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. |
Common Stock
|
1,500 |
| 2026-04-21 | Cross Shawn |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. |
Common Stock
|
2,845 |
| 2026-04-21 | Cross Shawn |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Stock Option (Right to Buy)
|
2,845 |
| 2026-04-21 | Cross Shawn |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
Common Stock
|
2,845 |
| 2026-04-20 | Cross Shawn |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3. |
Common Stock
|
7,714 |
| 2026-04-20 | Cross Shawn |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
Common Stock
|
7,714 |
| 2026-04-20 | Cross Shawn |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Stock Option (Right to Buy)
|
7,714 |
| 2026-03-17 | Froimson Mark |
Director |
Sell↓
|
Common Stock
|
500 |
| 2026-03-17 | SLONIN JONATHAN |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025. |
Common Stock
|
3,261 |
| 2026-02-11 | Teehan Brendan |
EVP, COO, HEAD OF COMMERCIAL |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
51,714 |
| 2026-02-11 | RIKER LAUREN |
Senior Vice President, Finance |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
19,273 |
| 2026-02-11 | Cross Shawn |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
49,091 |
| 2026-02-11 | Lee Frank D. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
261,818 |
| 2026-02-11 | WILLIAMS KRISTEN |
Chief Administrative Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
54,546 |
| 2026-02-11 | SLONIN JONATHAN |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Common Stock
|
54,546 |
| 2026-02-02 | RIKER LAUREN |
Senior Vice President, Finance |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.28, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3. |
Common Stock
|
4,000 |
| 2026-02-02 | WILLIAMS KRISTEN |
Chief Administrative Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. |
Common Stock
|
13,137 |
| 2026-01-30 | WILLIAMS KRISTEN |
Chief Administrative Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
17,134 |
| 2026-01-30 | RIKER LAUREN |
Senior Vice President, Finance |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
2,751 |
| 2026-01-30 | Teehan Brendan |
EVP, COO, HEAD OF COMMERCIAL |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
5,182 |
| 2026-01-30 | Lee Frank D. |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
41,488 |
| 2026-01-30 | SLONIN JONATHAN |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. |
Common Stock
|
6,168 |
| 2026-01-27 | Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Stock Option (Right to Buy)
|
39,291 |
| 2026-01-27 | Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
Other↑
|
No Securities Owned
|
0 |